Thromboembolic Events and Metabolic Hyperhomocysteinemia: Unraveling the Links and Clinical Implications

Thromboembolic events, represents one of the major causes of morbidity and mortality worldwide. While traditional risk factors, are well-established, metabolic hyperhomocysteinemia has emerged as a novel and potentially modifiable risk factor. Elevated levels of homocysteine, have been implicated in the pathogenesis of thromboembolic events, highlighting the importance of recognizing hyperhomocysteinemia in clinical practice. This article explores the relationship between thromboembolic events and Hyperhomocysteinemia by first reporting a case of a 20 years old man admitted to the CHU of Casablanca for a pulmonary embolism and in whom an hyperhomocysteinemia was diagnosed, then we will be highlighting the pathophysiology, clinical implications, and management strategies.